Dr. Prantesh Jain and Dr. Joshua Sabari delved into the numerous advances in NSCLC following 2025 ASCO, highlighting the ...

Highlights from ASCO 2025 in early-stage NSCLC include updates on CheckMate 816 on neoadjuvant nivolumab, NeoADAURA on osimertinib, and data on low-dose CT screening, presented by Dr Jonathan Goldman.

Lung cancer is the second most frequent cancer worldwide, and it accounts for 18% of all cancer-related deaths. Most cases of ...

When small-cell lung cancer (SCLC) has spread to distant parts of the body, it’s classified as extensive-stage, which applies ...

Global Non Small-Cell Lung Cancer Market, by Type The non-small cell lung cancer market grow at a CAGR of around 9.3% from 2021-2031.

Vaping might be safer than cigarette smoking, but they carry their own health risks. A New Jersey man’s electronic cigarette ...

The study is the first, to the researchers’ knowledge, to evaluate both survival and cost metrics across non-small cell lung ...

The FDA approved taletrectinib for ROS1-positive NSCLC. The agent shows efficacy for both new and pretreated cases, including ...

Antibody drug conjugates, or ADCs, are still holding on to their spot as one of the hottest areas in cancer care—and AbbVie, ...

Approval was based on results from the Phase II TRUST-I and TRUST-II trials, which demonstrated confirmed overall response ...

The drug, Ibtrozi, will now vie for market share in an indication where multiple large pharmaceutical companies have already ...

An international study, significantly shaped by Greek oncology, has unveiled a promising new treatment for small cell lung ...